Affiliation:
1. Institute of Pathology, University Medical Center Göttingen, University of Göttingen, 37075 Göttingen, Germany
Abstract
Thymomas (THs) are a unique group of heterogeneous tumors of the thymic epithelium. In particular, the subtypes B2 and B3 tend to be aggressive and metastatic. Radical tumor resection remains the only curative option for localized tumors, while more advanced THs require multimodal treatment. Deep sequencing analyses have failed to identify known oncogenic driver mutations in TH, with the notable exception of the GTF2I mutation, which occurs predominantly in type A and AB THs. However, there are multiple alternative non-mutational mechanisms (e.g., perturbed thymic developmental programs, metabolism, non-coding RNA networks) that control cellular behavior and tumorigenesis through the deregulation of critical molecular pathways. Here, we attempted to show how the results of studies investigating such alternative mechanisms could be integrated into a current model of TH biology. This model could be used to focus ongoing research and therapeutic strategies.
Reference139 articles.
1. Mature, long-lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis;Buckley;Ann. Neurol.,2001
2. Marx, A., and Chan, J.K.C. (2021). WHO Classification of Tumours. Thoracic Tumours, International Agency for Research on Cancer. [5th ed.]. WHO Classification of Tumours.
3. Thymoma related myasthenia gravis in humans and potential animal models;Marx;Exp. Neurol.,2015
4. The Integrated Genomic Landscape of Thymic Epithelial Tumors;Radovich;Cancer Cell,2018
5. Multimodality treatment of thymoma: A prospective study;Venuta;Ann. Thorac. Surg.,1997
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献